Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million

Company Overview - Cogent Biosciences, Inc. is a biotechnology company focused on precision therapies for genetically driven diseases, particularly in rare oncology indications [6] - The company specializes in selective tyrosine kinase inhibitors and aims to address critical treatment gaps through proprietary research and strategic partnerships [6] - As of February 13, 2026, Cogent's stock price was $36.53, with a market capitalization of $5.82 billion and a net income of -$294.37 million [4] Recent Developments - Rock Springs Capital Management disclosed a sale of 159,278 shares of Cogent Biosciences, valued at approximately $4.48 million, during the fourth quarter of 2025 [2] - Despite the reduction in stake, Cogent still represents 1.5% of Rock Springs' reportable assets under management, indicating continued confidence in the investment [7] - The company's share price increased by 346.6% over the past year, significantly outperforming the S&P 500 by 334.8 percentage points [7] Product Pipeline and Financial Position - Cogent is advancing its lead product candidate, bezuclastinib, targeting KIT mutations in systemic mastocytosis and gastrointestinal stromal tumors [8] - The company has submitted its NDA for bezuclastinib in December 2025 and is actively pursuing additional regulatory submissions in 2026 [10] - As of year-end 2025, Cogent reported cash and marketable securities totaling approximately $901 million, providing financial stability into 2028 [10] Market Context - The significant price rally of over 300% in the past year has prompted portfolio managers to reassess their positions, balancing between maintaining or trimming their investments [9] - The key focus for long-term investors will be whether Cogent can translate its regulatory momentum into successful commercial execution in the latter half of 2026 and beyond [11]